Dr. Bunker will focus on leading Research and Development (R&D) in San Diego, advancing the preclinical pipeline and optimizing the Company’s Integrated Discovery Engine.
Phase 2 study to assess efficacy and safety of once daily linperlisib in patients with advanced peripheral T/NK cell lymphoma
APIC is a contract development and manufacturing organization (CDMO) that offers a wide range of services such as synthetic route design, pilot manufacturing, investigational medical manufacturing, and commercial production, by making full use of integrated processes that combine organic synthesis technologies and biotechnologies it has cultivated over many years
The WAVEsystem with the WAVEcontrol 4.0 embedded
The expansion at CDMO facility in South Haven, will bring a new 4,000-gallon multi-use reactor train consisting of glass lined and stainless-steel materials of construction
Athos will perform multi-omic molecular and genetic analyses using biopsies from archived and de-identified Lahey IBD patient samples
COR803 is a novel small molecule 3CLpro inhibitor discovered and developed by Cortexyme based on its expertise in cysteine protease inhibition.
During the research term, Olema will contribute funding to Aurigene to facilitate ongoing discovery efforts.
The partnership aims to enhance HotSpot's drug discovery and development efforts by incorporating GOSTAR's high-quality, annotated datasets into HotSpot's machine learning (ML) and artificial intelligence (AI) models
Lonza to expand inhalation services by adding capabilities at its Tampa (US) site as part of its continued focus on providing bioavailability enhancement series for global customers
Subscribe To Our Newsletter & Stay Updated
